Trials / Recruiting
RecruitingNCT06080061
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionated accelerated radiation therapy | Hypofractionated accelerated radiation therapy |
Timeline
- Start date
- 2023-10-25
- Primary completion
- 2026-11-01
- Completion
- 2026-12-01
- First posted
- 2023-10-12
- Last updated
- 2026-04-07
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06080061. Inclusion in this directory is not an endorsement.